Clearmind Medicine Inc., a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced the publication of an international patent application in collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The patent application covers innovative psychedelic-based compounds designed for the treatment of mental health disorders and addiction.
Health Technology Insights: H.I.G. Capital Completes Acquisition of GetixHealth
Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “The publication highlights the potential of our collaboration with Yissum in our mission to transform mental health treatment through next-generation psychedelic-based therapeutics. Our collaboration with Yissum has yielded highly innovative compounds that go beyond the limitations of classical psychedelics. These new 3.0 compounds reflect our ongoing efforts to advancing safe, effective and scalable solutions for some of the most challenging and under-treated mental health and addiction disorders.”
The patent is part of Clearmind’s exclusive worldwide licensing agreement with Yissum to develop, research, manufacture, market and commercialize products derived from a patent-pending synthesis of psychedelic compounds, enriching the company’s innovative portfolio in addiction and mental health treatments.
Health Technology Insights: GoodRx Introduces New E-commerce Experience for Retail Pharmacies
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobeNewswire
